<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833348</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201640</org_study_id>
    <secondary_id>2020-A02279-30</secondary_id>
    <nct_id>NCT04833348</nct_id>
  </id_info>
  <brief_title>Quantification of Motor Function in Infants With Spinal Muscular Atrophy Treated With Innovative Therapies</brief_title>
  <acronym>IMUSMA</acronym>
  <official_title>Quantification of Motor Function in Infants With Spinal Muscular Atrophy Treated With Innovative Therapies, IMUSMA Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to propose a method for quantifying motor function in infants with&#xD;
      spinal muscular atrophy treated with innovative therapies using inertial sensors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infantile spinal muscular atrophy is a common disease (the second most common fatal autosomal&#xD;
      recessive disease after cystic fibrosis), neurodegenerative disorders of childhood causing&#xD;
      severe motor impairment and a risk to life through respiratory failure in the most severe&#xD;
      forms.&#xD;
&#xD;
      Innovative therapies (gene therapy or pharmacogenetics) have recently proven their&#xD;
      effectiveness on survival criteria. Nevertheless, the motor benefit of these therapies must&#xD;
      be evaluated more precisely.&#xD;
&#xD;
      Currently, the reference methods for motor development assessment are fairly robust&#xD;
      semi-quantitative motor scales that lack sensitivity and do not reflect function (CHOPINTEND,&#xD;
      HINE, BAYLEY SCALE, MFM and CGI-scale).&#xD;
&#xD;
      Advances in recent techniques have enabled the emergence of non-invasive, secure, easy-to-use&#xD;
      inertial sensors in routine clinical practice that allow quantification of infant movements.&#xD;
&#xD;
      The aim of the study is to propose a method for quantifying motor function in infants with&#xD;
      spinal muscular atrophy treated with innovative therapies using inertial sensors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the 95th percentile of the norm of acceleration</measure>
    <time_frame>Month 0 to month 24</time_frame>
    <description>95th percentile of the norm of the acceleration of the feet and the arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the 95th percentile of the norm of angular velocity</measure>
    <time_frame>Month 0 to month 24</time_frame>
    <description>95th percentile of the norm of angular velocity of the feet and the arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the 95th percentile of the accelerations allong the vertical axis and the horizontal plane</measure>
    <time_frame>Month 0 to month 24</time_frame>
    <description>95th percentile of the accelerations of the feet and the arms the vertical axis and the horizontal plane.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the 95th percentile of the angular velocities allong the vertical axis and the horizontal plane.</measure>
    <time_frame>Month 0 to month 24</time_frame>
    <description>95th percentile of the angular velocities of the feet and the arms the vertical axis and the horizontal plane.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the acceleration's entropy</measure>
    <time_frame>Month 0 to month 24</time_frame>
    <description>Acceleration's entropy computed in the different axis of the feet and the arms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants with spinal muscular atrophy cared by the Neuromuscular Reference Center at Necker Hospital and eligible for innovative therapy (gene therapy or pharmacogenetics)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Motor function measurement using inertial sensors</intervention_name>
    <description>Measurement of motor skills at M0: start of the administration of the innovative therapy and then 1 month, 3 months, 6 months, 1 year and then 2 years later:&#xD;
Free motor skills in the supine position&#xD;
Motricity in the supine position stimulated by a play frame&#xD;
Measurement of the proximal and distal activity of the upper limbs in motor skills stimulated by the play gantry&#xD;
Measurement of activity in a supported sitting position Longitudinal study, the subject is his own control</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants of both sexes&#xD;
&#xD;
          -  Suffering from spinal muscular atrophy (diagnosis by genetic study &quot;homozygous&#xD;
             deletion of SMN1&quot;)&#xD;
&#xD;
          -  Followed up by the Necker Neuromuscular Reference Center (GNMH)&#xD;
&#xD;
          -  Eligible for innovative therapy (gene therapy or pharmacogenetics)&#xD;
&#xD;
               -  age of onset of the disease &lt;1 year&#xD;
&#xD;
               -  no severe respiratory impairment (dependence on ventilatory support for more than&#xD;
                  16 hours per day) or bulbar involvement&#xD;
&#xD;
               -  decision of treatment by a Multidisciplinary Consultation Meeting national of&#xD;
                  experts&#xD;
&#xD;
          -  Benefiting from social security scheme&#xD;
&#xD;
          -  Informed consent signed by holders of parental authority and the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-consent of one of the holders of parental authority&#xD;
&#xD;
          -  Respiratory instability (dependence on ventilatory support for more than 16 hours per&#xD;
             day) or hemodynamics&#xD;
&#xD;
          -  Contraindication to innovative therapy&#xD;
&#xD;
          -  History of another disease impacting motor skills (neonatal suffering, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle DESGUERRE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian TERVIL, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Borelli - Université Paris Descartes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle DESGUERRE, MD, PhD</last_name>
    <phone>1 44 49 48 56</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.desguerre@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène MOREL</last_name>
    <phone>1 71 19 63 46</phone>
    <phone_ext>+33</phone_ext>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle DESGUERRE, MD, PhD</last_name>
      <phone>1 44 49 48 56</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.desguerre@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Rémi BARROIS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine BARNERIAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal muscular atrophy</keyword>
  <keyword>Innovative therapies</keyword>
  <keyword>Motor function</keyword>
  <keyword>Wearable inertial sensors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

